New JTCC Studies Demonstrate Clinical and Economic Value of Genomic Profiling in Improving Care and Outcomes in Non-Small Cell Lung Cancer and Breast Cancer

COTA Collaborates with Novartis Pharmaceuticals Corporation Cota Healthcare, the leading data and technology platform for value-based precision medicine, today announced the signing of a major, multi-year collaboration with Novartis Pharmaceuticals Corporation to help improve clinical and cost outcomes for breast cancer patients. As part of this agreement, which expands significantly on the previous announced collaboration entered into January 2016, teams from across Novartis Pharmaceuticals Corporation will leverage Cota's research-grade, real-world evidence, web-based analysis and visualization tools, and be supported by Cota's medical, data science, and technology experts. Utilizing the real-world evidence and technology platform supplied by Cota is expected to enable Novartis Pharmaceuticals Corporation to accelerate clinical development of new therapies for breast cancer and identify which patients will benefit most. Read Full Release

Introducing Cota OCM™—A Solution for Practices Moving to Value-based Programs Over the last year, our team at Cota has worked closely with providers and CMS—preparing for the eventual move to value-based payment under MACRA by studying the complexities of the law and building an OCM-specific technology solution on top of our CNA Guided Care™ platform. To address the obvious policy question up front: While the new administration has already planned or implemented sweeping changes across other areas, all indications (including these comments from former CMS head Andy Slavitt) point to Alternative Payment Models (APMs) and value-based payments sticking around for the long haul. In this post, we want to share what we’ve learned so far and officially announce Cota’s new technology solution specifically designed to help providers address the challenges and opportunities during this exciting time in the move value-based healthcare. Jump straight to the Cota OCM product announcement here. Read Full Release

BMP Invests in COTA Boston Millennia Partners Invests in Cota, Inc. Boston, MA, December 2016, Boston Millennia Partners is pleased to announce its investment in Cota, Inc. as part of an $18 million growth equity round. Cota is a New York City based cancer outcomes and data tracking company that uses a patented digital classification system to assess patient results on specific treatment protocols. Cota’s customers include pharmaceutical companies, healthcare providers and insurance companies. The company has partnerships with several major pharmaceutical companies in the U.S. including Novartis and Celgene, and with data provider Foundation Medicine. The company has received strategic investments from Novartis, Celgene, Foundation Medicine and Horizon Healthcare. Read Full Release